Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours — CLARINET

Endocrine Tumors Clinical Trial

Official title:
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Status Completed

Clinical Trial Summary

The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00353496
Study type	Interventional
Source	Ipsen
Contact
Status	Completed
Phase	Phase 3
Start date	June 2006
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase 2
Recruiting	`NCT01005654` - Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Terminated	`NCT00180960` - Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia	Phase 2
Recruiting	`NCT01109394` - Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies